Complement C4d Antibody (C4D204), Novus Biologicals™

Mouse Monoclonal Antibody

Catalog Number	Mfr. No.	Quantity
NBP234234F	Novus Biologicals NBP2342340.02MG	0.02 mg
NBP234234A	Novus Biologicals NBP2342340.1MG	0.1 mg
NBP234234B	Novus Biologicals NBP2342340.2MG	0.2 mg

Description

Complement C4d Monoclonal specifically detects Complement C4d in Human samples. It is validated for ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin.

Specifications

• Antigen: Complement C4d
• Dilution: Immunocytochemistry/Immunofluorescence 1:50-1:100, Immunohistochemistry-Paraffin 1:200-1:400, Immunohistochemistry-Frozen 1:200-1:400
• Classification: Monoclonal
• Form: Purified
• Regulatory Status: RUO
• Formulation: PBS with 0.05% BSA. with 0.05% Sodium Azide
• Gene ID (Entrez): 720
• Immunogen: Recombinant human Complement 4d protein
• Primary or Secondary: Primary
• Content And Storage: Store at 4C.
• Molecular Weight of Antigen: 192 kDa

• Clone: C4D204
• Applications: Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen)
• Conjugate: Unconjugated
• Host Species: Mouse
• Target Species: Human
• Gene Accession No.: P0C0L4
• Gene Symbols: C4A
• Isotype: IgG1 κ
• Purification Method: Protein A purified
• Test Specificity: This MAb is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound C4d.C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of Abs to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product Complement 4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. It has been shown to be a significant predictor of transplant kidney graft survival. Anti-C4d, combined with anti-C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment.